Cailian Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cailian Liu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Jedd D. Wolchok
Weill Cornell Medicine 29 New York, NY
4 shared publications - Taha Merghoub
Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, USA
3 shared publications - Andrew Chow
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications - Jianda Yuan
Immune Monitoring Core, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 386, New York, NY 10065 USA
2 shared publications - Nathan Suek
Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy
2 shared publications - Sadna Budhu
Weill Cornell Medicine 5 New York, New York
2 shared publications
Latest Publications
- Open Access
- 15 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (18)
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
In addition to playing a major role in tumor cell biology, p53 generates a microenvironment that promotes antitumor immune surveillance via tumor-associated macrophages. We examined whether increasing p53 signaling in the tumor microenvironment influences antitumor T cell immunity. Our findings indicate that increased p53 signaling induced either pharmacologically with APR-246 (eprenetapopt) or in p53-overexpressing transgenic mice can disinhibit antitumor T cell immunity and augment the efficacy of immune checkpoint blockade. We demonstrated that increased p53 expression in tumor-associated macrophages induces canonical p53-associated functions such as senescence and activation of a p53-dependent senescence-associated secretory phenotype. This was linked with decreased expression of proteins associated with M2 polarization by tumor-associated macrophages. Our preclinical data led to the development of a clinical trial in patients with solid tumors combining APR-246 with pembrolizumab. Biospecimens from select patients participating in this ongoing trial showed that there was a suppression of M2-polarized myeloid cells and increase in T cell proliferation with therapy in those who responded to the therapy. Our findings, based on both genetic and a small molecule–based pharmacological approach, suggest that increasing p53 expression in tumor-associated macrophages reprograms the tumor microenvironment to augment the response to immune checkpoint blockade.
- 15 September 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (18)
Open AccessIncreased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
In addition to playing a major role in tumor cell biology, p53 generates a microenvironment that promotes antitumor immune surveillance via tumor-associated macrophages. We examined whether increasing p53 signaling in the tumor microenvironment influences antitumor T cell immunity. Our findings indicate that increased p53 signaling induced either pharmacologically with APR-246 (eprenetapopt) or in p53-overexpressing transgenic mice can disinhibit antitumor T cell immunity and augment the efficacy of immune checkpoint blockade. We demonstrated that increased p53 expression in tumor-associated macrophages induces canonical p53-associated functions such as senescence and activation of a p53-dependent senescence-associated secretory phenotype. This was linked with decreased expression of proteins associated with M2 polarization by tumor-associated macrophages. Our preclinical data led to the development of a clinical trial in patients with solid tumors combining APR-246 with pembrolizumab. Biospecimens from select patients participating in this ongoing trial showed that there was a suppression of M2-polarized myeloid cells and increase in T cell proliferation with therapy in those who responded to the therapy. Our findings, based on both genetic and a small molecule–based pharmacological approach, suggest that increasing p53 expression in tumor-associated macrophages reprograms the tumor microenvironment to augment the response to immune checkpoint blockade.
- Open Access
- 22 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (20)
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
Only a subset of cancer patients responds to checkpoint blockade inhibition in the clinic. Strategies to overcome resistance are promising areas of investigation. Targeting glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) has shown efficacy in preclinical models, but GITR engagement is ineffective in controlling advanced, poorly immunogenic tumors, such as B16 melanoma, and has not yielded benefit in clinical trials. The alkylating agent cyclophosphamide (CTX) depletes regulatory T cells (Tregs), expands tumor-specific effector T cells (Teffs) via homeostatic proliferation, and induces immunogenic cell death. GITR agonism has an inhibitory effect on Tregs and activates Teffs. We therefore hypothesized that CTX and GITR agonism would promote effective antitumor immunity. Here we show that the combination of CTX and GITR agonism controlled tumor growth in clinically relevant mouse models. Mechanistically, we show that the combination therapy caused tumor cell death, clonal expansion of highly active CD8 + T cells, and depletion of Tregs by activation-induced cell death. Control of tumor growth was associated with the presence of an expanded population of highly activated, tumor-infiltrating, oligoclonal CD8 + T cells that led to a diminished TCR repertoire. Our studies show that the combination of CTX and GITR agonism is a rational chemoimmunotherapeutic approach that warrants further clinical investigation.
- 22 October 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (20)
Open AccessCyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
Only a subset of cancer patients responds to checkpoint blockade inhibition in the clinic. Strategies to overcome resistance are promising areas of investigation. Targeting glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) has shown efficacy in preclinical models, but GITR engagement is ineffective in controlling advanced, poorly immunogenic tumors, such as B16 melanoma, and has not yielded benefit in clinical trials. The alkylating agent cyclophosphamide (CTX) depletes regulatory T cells (Tregs), expands tumor-specific effector T cells (Teffs) via homeostatic proliferation, and induces immunogenic cell death. GITR agonism has an inhibitory effect on Tregs and activates Teffs. We therefore hypothesized that CTX and GITR agonism would promote effective antitumor immunity. Here we show that the combination of CTX and GITR agonism controlled tumor growth in clinically relevant mouse models. Mechanistically, we show that the combination therapy caused tumor cell death, clonal expansion of highly active CD8 + T cells, and depletion of Tregs by activation-induced cell death. Control of tumor growth was associated with the presence of an expanded population of highly activated, tumor-infiltrating, oligoclonal CD8 + T cells that led to a diminished TCR repertoire. Our studies show that the combination of CTX and GITR agonism is a rational chemoimmunotherapeutic approach that warrants further clinical investigation.
- Open Access
- 16 June 2015
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 3 (1) , 23
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Background Ipilimumab improves overall survival in a subset of patients with metastatic melanoma. Peripheral blood T cell receptor (TCR) repertoire diversity has been associated with favorable outcomes in patients with cancer, but its relevance as a biomarker for ipilimumab outcomes remains unknown. Findings In this pilot study, we analyzed the pre-treatment peripheral blood TCR repertoire in 12 patients with metastatic melanoma who received ipilimumab at 3 mg/kg (clinical benefit, n = 4; no clinical benefit, n = 8). TCR diversity was evaluated using a polymerase chain reaction assay which measures TCR combinatorial diversity between V and J genes from genomic DNA. TCR repertoire diversity was studied through richness (observed V-J rearrangements) and evenness (similarity between the frequencies of specific V-J rearrangements). The Wilcoxon rank sum test was used to compare patients with clinical benefit and those without. Association with benefit in a dichotomized analysis was assessed through a Fisher’s exact test. Overall survival was studied through log-rank analysis. There was a significant difference in richness (p = 0.033) and evenness (p = 0.028) between patients with and without clinical benefit. Dichotomized analysis showed that none of the patients with low richness (n = 0/5, p = 0.081) nor low evenness (n = 0/7, p = 0.01) achieved clinical benefit. There were no significant differences in overall survival. Conclusions In this small group of patients, baseline TCR diversity in the peripheral blood was associated with clinical outcomes. Further investigation is ongoing in larger cohorts of patients to explore these preliminary findings and determine whether TCR diversity can be used as a predictive biomarker in cancer immunotherapy.
- 16 June 2015
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 3 (1) , 23
Open AccessPeripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Background Ipilimumab improves overall survival in a subset of patients with metastatic melanoma. Peripheral blood T cell receptor (TCR) repertoire diversity has been associated with favorable outcomes in patients with cancer, but its relevance as a biomarker for ipilimumab outcomes remains unknown. Findings In this pilot study, we analyzed the pre-treatment peripheral blood TCR repertoire in 12 patients with metastatic melanoma who received ipilimumab at 3 mg/kg (clinical benefit, n = 4; no clinical benefit, n = 8). TCR diversity was evaluated using a polymerase chain reaction assay which measures TCR combinatorial diversity between V and J genes from genomic DNA. TCR repertoire diversity was studied through richness (observed V-J rearrangements) and evenness (similarity between the frequencies of specific V-J rearrangements). The Wilcoxon rank sum test was used to compare patients with clinical benefit and those without. Association with benefit in a dichotomized analysis was assessed through a Fisher’s exact test. Overall survival was studied through log-rank analysis. There was a significant difference in richness (p = 0.033) and evenness (p = 0.028) between patients with and without clinical benefit. Dichotomized analysis showed that none of the patients with low richness (n = 0/5, p = 0.081) nor low evenness (n = 0/7, p = 0.01) achieved clinical benefit. There were no significant differences in overall survival. Conclusions In this small group of patients, baseline TCR diversity in the peripheral blood was associated with clinical outcomes. Further investigation is ongoing in larger cohorts of patients to explore these preliminary findings and determine whether TCR diversity can be used as a predictive biomarker in cancer immunotherapy.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 3003
The neoantigen landscape underlying clinical response to ipilimumab.
3003 Background: Ipilimumab, an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), prolongs overall survival and can produce durable tumor regression in patients with advanced melanoma. Ipilimumab activates cytotoxic T-lymphocytes and enables them to destroy tumor cells. However, the molecular determinants of response to ipilimumab are unknown. Methods: Fresh frozen tumor DNA (and matching blood) from 25 melanoma patients treated with ipilimumab was subjected to whole exome sequencing. Exon capture was performed using the SureSelect Human All Exon 50MB kit (Agilent). Enriched exome libraries were sequenced on the HiSeq 2000 platform (Illumina) to a mean coverage of 103X. Somatic mutations and candidate somatic neoantigens generated from these mutations were identified and characterized. Results: Our cohort included complete responders (CR) and nonresponders (NR). Mutational burden ranged from 1-1121 mutations per tumor. Mutational load was significantly associated with clinical response (p=0.028, CR vs. NR, Fisher’s Exact Test), but alone was not sufficient to predict response. Using genome-wide somatic neoepitope analysis, we defined candidate tumor neoantigens and identified a neoantigen landscape that is specifically present in tumors with complete responses to ipilimumab. These somatic neoepitopes share consensus sequences with experimentally validated antigens from a variety of pathogens. Furthermore, in four of six CR patients, a mutation led to the generation of a consensus amino acid sequence previously identified as necessary for T-cell recognition of melanoma antigen recognized by T-cells (MART-1). Conclusions: Somatic mutations and concomitant generation of neoepitopes in melanoma tumors confers enhanced antigenicity and response to the immune checkpoint modulator ipilimumab. Our study defines the neoantigen landscape in responders to ipilimumab, provides a rationale for examining the exomes of patients for whom ipilimumab is being considered, and builds a foundation for understanding the molecular determinants of response to cancer immunotherapy.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , 3003
The neoantigen landscape underlying clinical response to ipilimumab.
3003 Background: Ipilimumab, an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), prolongs overall survival and can produce durable tumor regression in patients with advanced melanoma. Ipilimumab activates cytotoxic T-lymphocytes and enables them to destroy tumor cells. However, the molecular determinants of response to ipilimumab are unknown. Methods: Fresh frozen tumor DNA (and matching blood) from 25 melanoma patients treated with ipilimumab was subjected to whole exome sequencing. Exon capture was performed using the SureSelect Human All Exon 50MB kit (Agilent). Enriched exome libraries were sequenced on the HiSeq 2000 platform (Illumina) to a mean coverage of 103X. Somatic mutations and candidate somatic neoantigens generated from these mutations were identified and characterized. Results: Our cohort included complete responders (CR) and nonresponders (NR). Mutational burden ranged from 1-1121 mutations per tumor. Mutational load was significantly associated with clinical response (p=0.028, CR vs. NR, Fisher’s Exact Test), but alone was not sufficient to predict response. Using genome-wide somatic neoepitope analysis, we defined candidate tumor neoantigens and identified a neoantigen landscape that is specifically present in tumors with complete responses to ipilimumab. These somatic neoepitopes share consensus sequences with experimentally validated antigens from a variety of pathogens. Furthermore, in four of six CR patients, a mutation led to the generation of a consensus amino acid sequence previously identified as necessary for T-cell recognition of melanoma antigen recognized by T-cells (MART-1). Conclusions: Somatic mutations and concomitant generation of neoepitopes in melanoma tumors confers enhanced antigenicity and response to the immune checkpoint modulator ipilimumab. Our study defines the neoantigen landscape in responders to ipilimumab, provides a rationale for examining the exomes of patients for whom ipilimumab is being considered, and builds a foundation for understanding the molecular determinants of response to cancer immunotherapy.